Antiplatelet therapy after percutaneous coronary intervention

Area of Science:

• Cardiology
• Inflammation Research
• Thrombosis Studies

Background:

• Coronary artery disease (CAD) involves complex interactions between inflammation, thrombosis, platelet aggregation, and hyperlipidemia.
• Inflammatory markers aid risk stratification in acute coronary syndromes (ACS).
• ACS patients often present with an inflammatory state requiring antiplatelet therapy, including aspirin and clopidogrel.

Purpose of the Study:

• To review the role of inflammation and antiplatelet therapy in patients with coronary artery disease.
• To discuss the benefits and risks of dual antiplatelet therapy (DAPT) in medically treated and stented ACS patients.
• To highlight the challenges and future directions in managing stent thrombosis and assessing platelet function.

Main Methods:

• Literature review of studies on inflammation, thrombosis, and antiplatelet therapy in CAD.
• Analysis of outcomes associated with DAPT in ACS patients, both medically managed and post-stenting.
• Discussion of the implications of drug-eluting stents (DES) and the emerging issue of late stent thrombosis.

Main Results:

• DAPT is associated with improved outcomes in medically treated ACS patients and is crucial after intracoronary stent placement.
• DES use has decreased restenosis but increased the risk of late subacute stent thrombosis, a serious complication.
• Current DAPT durations are evolving, with longer treatment periods being increasingly adopted clinically.

Conclusions:

• Extended DAPT is recommended for patients with DES to mitigate the risk of late stent thrombosis.
• Accurate assessment of platelet function and inflammation is needed for personalized antiplatelet therapy strategies.
• Future research should focus on refining platelet function tests and integrating inflammation assessment for targeted treatment in CAD.